A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers.
Paul K PaikRachel K KimLinda AhnAndrew J PlodkowskiAi NiMark T A DonoghuePhilip JonssonMiguel Villalona-CaleroKenneth NgDaniel C McFarlandJohn J FioreAfsheen IqbalJuliana EngMark G KrisCharles M RudinPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Gemcitabine plus ABP was a safe, tolerable, and effective first-line therapy for patients with chemotherapy-naïve SQCLCs, with an ORR and median PFS substantially higher than carboplatin doublet regimens and efficacy comparable with carboplatin plus taxane plus pembrolizumab.